Skip to content
  • Home
  • About Us
  • Services
  • Courses
  • Online Learning
  • News and Events
  • Contact Us
  • Home
  • About Us
  • Services
  • Courses
  • Online Learning
  • News and Events
  • Contact Us

EMA

  1. Home>
  2. News and Events>
  3. EMA
Read more about the article EMA recommends authorisation of first therapy to treat rare genetic disorder

EMA recommends authorisation of first therapy to treat rare genetic disorder

  • Post published:June 16, 2022

EMA has recommended granting a marketing authorisation in the European Union for Upstaza (eladocagene exuparvovec). This is a gene therapy for the treatment of adult and paediatric patients with severe…

Continue ReadingEMA recommends authorisation of first therapy to treat rare genetic disorder
Read more about the article EMA positive opinion for new gene therapy to treat multiple myeloma

EMA positive opinion for new gene therapy to treat multiple myeloma

  • Post published:April 7, 2022

EMA has recommended granting a conditional marketing authorisation for Carvykti (ciltacabtagene autoleucel) and it is now pending for European Commission decision.Medicines for human use are eligible for conditional marketing authorisation if…

Continue ReadingEMA positive opinion for new gene therapy to treat multiple myeloma
Read more about the article COVID-19 vaccines and treatments approved by the EMA

COVID-19 vaccines and treatments approved by the EMA

  • Post published:April 22, 2021

The global effort on fighting the on-going COVID-19 pandemic, declared so by the World Health Organization in 11 March 2020, is bearing fruit. The endeavor made in the last year…

Continue ReadingCOVID-19 vaccines and treatments approved by the EMA

Revio is a Regulatory Affairs Consultancy – Created to support biopharmaceutical companies and public institutions, working with Advanced Therapy Medicinal Products (ATMPs)

Facebook-f Twitter Pinterest Linkedin

About

Home

About Us

Services

News & Events

Contact Us

Contact

TELEPHONES

+34 656 659 636

EMAIL

regaffairs@reviopharma.com

Legal

Cookies Policy

Data Protection

Legal Notice

Privacy policy

Social Networks

Copyright © 2024 – All Right Reserved – Powered by: Headteam.marketing

Reviopharma
×

Cart